FDA grants fast track designation to CPI-613 for pancreatic cancer

The FDA granted fast track designation to devimistat for the treatment of pancreatic cancer, according to the agent’s manufacturer.Devimistat (CPI-613, Rafael Pharmaceuticals) targets enzymes in the mitochondria of cancer cells that are involved in cancer cell energy metabolism.The agent is designed to selectively target the mitochondrial tricarboxylic acid cycle in cancer cells. This process is essential to tumor cell multiplication and survival.“Receiving fast track designation is a significant milestone in our fight against pancreatic cancer,” Sanjeev Luther, presidentRead More

Share on facebook
Share on twitter
Share on linkedin